Genmab — Januar 2019
-
yes, and there is a link to another article ( we have seen before ) it was $6 "There is still much uncertainty around Darzalex’s weighty 2024 forecast of $6bn, however; an unexplained price cut earlier this year shook investor confidence, and many analysts will be waiting to see how the drug fares in front-line settings to sharpen their sales predictions."
-
Winkel for 2 år siden: “It could work in other blood cancers as well as in solid tumours. So that means $13 billion potential if it would work in all the indications,” Van de Winkel told Reuters. https://endpts.com/genmab-outlines-a-megablockbuster-future-for-itself-and-jj-as-darzalex-gains-market-traction/
-
Hvornår venter vi nyt angående solide?
-
Ok. Vi må håbe på noget positivt i løbet af året.
-
Checkmate142 dara-nivo i coloncancer kører stadig. Data kan forventes sent i år. Checkmate358 rekrutterer stadig (virus-ass cancer). Data måske her i foråret. Og så er der dara-nivo i diverse solide, som stoppede rekruttering tidligt, men som stadig er aktivt. https://www.clinicaltrials.gov/ct2/results?cond=&term=nivolumab+daratumumab&cntry=&state=&city=&dist=&Search=Search
-
-
God morgen :-)¨
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind